Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 3 Jul 2006 |
| Trading in the demerging Orion's shares on the Helsinki Stock Exchange ends today, 30 June 2006 | 30 Jun 2006 |
| Demerging Orion publishes Listing Particulars of new Orion and Oriola-KD | 21 Jun 2006 |
| Orion?s Wholesale and Distribution Division to reduce about 50 employees in Finnish distribution ope | 20 Jun 2006 |
| Orion Corporation share capital increase and the permission to decrease the premium fund have been e | 15 Jun 2006 |